MedPAC says that for two or three years CMS likely would pay 340B hospitals more for the expensive new Alzheimer’s drug Aduhelm than it normally would for a Part B drug.
MedPAC says that for two or three years CMS likely would pay 340B hospitals more for the expensive new Alzheimer’s drug Aduhelm than it normally would for a Part B drug.
*Sign up for news summaries and alerts from 340B Report